Author: Hidetaka Watanabe ; Yuichiro Yoshino ; Masashi Odo ; Toshikatsu Igata ; Eiko Nagamoto ; Kanako Yoshitsugu ; Hiromitsu Noguchi ; Akihiko Fujisawa

A 28-year-old man undergoing treatment for hemophagocytic syndrome developed Paecilomyces lilacinus infection in skin ulcers on the face and in the tracheotomy stoma. While his bone marrow was suppressed by chemotherapy with dexamethasone, cyclosporin and etoposide for hemophagocytic syndrome, dental infection led to subacute necrotizing fasciitis caused by Pseudomonas aeruginosa on the right side of the face, resulting in a large area of soft tissue defects. Etoposide was discontinued, and prophylactic treatment with itraconazole was initiated. The ulcers resulting from necrotizing fasciitis were treated conservatively using trafermin and alprostadil alfadex ointment 0.003 %, and near-complete re-epithelialization occurred, except on the right lower eyelid, right buccal mucosa and perioral area. However, 6 weeks later, pustules/crusts started to form and break down repeatedly, leading to expansion of tissue defects on the face. Direct microscopic examination revealed fungal elements, and fungal culture identified Paecilomyces lilacinus suspicious twice some other day. Based on DNA extraction from the isolated fungus, this fungal strain was identified as Paecilomyces lilacinus. Cyclosporin and itraconazole were discontinued, and treatment with liposomal amphotericin B and a tapering dose of steroids was initiated. Cure was achieved in approximately 2.5 months after treatment initiation, and no relapse has been observed. The most important factor that ultimately contributed to the resolution of fungal infection might have been release of immunosuppression by discontinuing cyclosporin and tapering steroids.

01 Feb 2012·Review of Scientific InstrumentsQ4 · ENGINEERING & TECHNOLOGY

A Tandetron™ as proton injector for the eye tumor therapy in Berlin

Q4 · ENGINEERING & TECHNOLOGY

Article

Author: Mueller, U. ; Denker, A. ; Damerow, T. ; Roehrich, J. ; Reinholz, U. ; Hahn, W.

The therapy of eye tumors with fast protons is an excellent tool giving very high local control rates. At the Helmholtz-Zentrum Berlin (HZB) almost 1800 patients were treated since 1998. A 2 MV Tandetron™ was installed as injector for the k = 132 HZB cyclotron. Using the standard 358 duoplasmatron ion source with direct extraction of negative hydrogen ions an extremely stable proton beam can be delivered, both on the short-term and the long-term scale. The hair-needle filaments made from thoriated tungsten wires have safe operation times of more than 1000 h.

01 Dec 2008·Kyobu geka. The Japanese journal of thoracic surgery

[Interrupted aortic arch type B survived after single stage repair and continuous hemodiafiltration; report of a case].

Article

Author: Minakawa, M ; Daitoku, K ; Suzuki, Y ; Yamauchi, S ; Fukui, K ; Fukuda, I

A 14-day-old, 2,042 g neonate with interrupted aortic arch (IAA) type B was admitted to our hospital because of respiratory failure. Although alprostadil and alprostadil alfadex were used to keep the ductus arteriosus open, her congestive heart failure became worse and anuria and metabolic acidosis started to appear. We performed single-stage repair for her at 14 days old. Continuous hemodiafiltration (CHDF) was initiated immediately after the operation and peritoneal dialysis was started after paralytic ileus improved. CHDF improved her renal function and she was discharged at postoperative day 84. We conclude that CHDF is effective for neonates with acute renal failure although circulation management is rather difficult.

100 Deals associated with Alprostadil Alfadex

External Link

KEGG	Wiki	ATC	Drug Bank
D02705	-	C01EA01 G04BE01	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Erectile Dysfunction	Japan	Maruishi Pharmaceutical Co., Ltd.	23 Feb 2011
Rest pain	Japan	Maruishi Pharmaceutical Co., Ltd.	29 May 1987
Intraoperative hypertension	Japan	Maruishi Pharmaceutical Co., Ltd.	31 Mar 1987
Peripheral Vascular Diseases	Japan	Nippon Chemiphar Co., Ltd.	27 Aug 1979
Pressure Ulcer	Japan	Nippon Chemiphar Co., Ltd.	27 Aug 1979
Skin Ulcer	Japan	Nippon Chemiphar Co., Ltd.	27 Aug 1979
Thromboangiitis Obliterans	Japan	Nippon Chemiphar Co., Ltd.	27 Aug 1979
Ulcer	Japan	Nippon Chemiphar Co., Ltd.	27 Aug 1979

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis